Recent advances in oral vaccine development

Smet, Rita De; Allais, Liesbeth; Cuvelier, Claude

doi:10.4161/hv.28166

Cited by 70 publications

(34 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particulate β-glucans can also be used as adjuvants for chemotherapy as well as adjuvants in vaccines for their additional effects on the immune system (61,62). They could enhance hematopoietic responses in animal models under chemotherapy, by increasing interleukin-6 levels (63).…”

Section: Particle Sizementioning

confidence: 99%

Structure-Functional Activity Relationship of β-Glucans From the Perspective of Immunomodulation: A Mini-Review

et al. 2020

View full text Add to dashboard Cite

β-Glucans are a heterogeneous group of glucose polymers with a common structure comprising a main chain of β-(1,3) and/or β-(1,4)-glucopyranosyl units, along with side chains with various branches and lengths. β-Glucans initiate immune responses via immune cells, which become activated by the binding of the polymer to specific receptors. However, β-glucans from different sources also differ in their structure, conformation, physical properties, binding affinity to receptors, and thus biological functions. The mechanisms behind this are not fully understood. This mini-review provides a comprehensive and up-to-date commentary on the relationship between β-glucans' structure and function in relation to their use for immunomodulation.

show abstract

Section: Particle Sizementioning

confidence: 99%

Structure-Functional Activity Relationship of β-Glucans From the Perspective of Immunomodulation: A Mini-Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Such bioencapsulation may subsequently provide additional protection from degradation in the digestive tract, even though HBcAg is relatively stable in the acidic environment of the stomach [24]. Hence, considering both findings, orally administered plant-associated HBcAg passes through the intestine, activating Gut Associated Lymphoid Tissue (GALT), as also described for other antigens [25,26].…”

Section: Discussionmentioning

confidence: 93%

Parenteral–Oral Immunization with Plant-Derived HBcAg as a Potential Therapeutic Vaccine against Chronic Hepatitis B

et al. 2019

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) is the cause of severe liver damage, cirrhosis, and hepatocellular carcinoma for over 240 million people worldwide. Nowadays, several types of treatment are being investigated, including immunotherapy using hepatitis B core antigen (HBcAg) assembled into highly immunogenic capsid-like particles (CLPs). Immunogenicity of plant-produced and purified HBcAg, administered parenterally or intranasally, was previously reported. In this study, a novel parenteral–oral vaccination scheme is proposed using plant-derived HBcAg preparations. The antigen for injection was obtained via transient expression in Nicotiana benthamiana. HBcAg-producing transgenic lettuce was lyophilized and used as an orally delivered booster. The intracellular location of plant-produced HBcAg CLPs implies additional protection in the digestive tract during oral immunization. BALB/c mice were intramuscularly primed with 10 µg of the purified antigen and orally boosted twice with 5 or 200 ng of HBcAg. A long-lasting and significant systemic response after boosting with 200 ng HBcAg was induced, with anti-HBc titer of 25,000. Concomitantly, an insignificant mucosal response was observed, with an S-IgA titer of only 500. The profile of IgG isotypes indicates a predominant Th1 type of immune response, supplemented by Th2, after injection–oral vaccination. The results demonstrate that a low dose of parenteral–oral immunization with plant-derived HBcAg can elicit a specific and efficient response. This study presents a potential new pathway of CHB treatment.

show abstract

“…Furthermore, S. cerevisiae -based yeast vaccines can potentially be used as oral vaccines owing to their edibility. The oral vaccination could elicit both humoral and cellular immune response at systematic and mucosal sites [54]. However, their stability and immunogenicity need to be carefully characterized when delivered to the gastrointestinal tract.…”

Section: Resultsmentioning

confidence: 99%

Yeast Surface-Displayed H5N1 Avian Influenza Vaccines

Han

Jin

Karlsson

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.

show abstract

Recent advances in oral vaccine development

Cited by 70 publications

References 105 publications

Structure-Functional Activity Relationship of β-Glucans From the Perspective of Immunomodulation: A Mini-Review

Structure-Functional Activity Relationship of β-Glucans From the Perspective of Immunomodulation: A Mini-Review

Parenteral–Oral Immunization with Plant-Derived HBcAg as a Potential Therapeutic Vaccine against Chronic Hepatitis B

Yeast Surface-Displayed H5N1 Avian Influenza Vaccines

Contact Info

Product

Resources

About